Navigation Links
Modest Cardiac Benefit From Chelation Therapy Not Enough to OK Use: Experts

By E.J. Mundell
HealthDay Reporter

TUESDAY, March 26 (HealthDay News) -- Results from a major trial on controversial chelation therapy for patients with a history of heart attack find a modest benefit from the expensive treatment, but experts conclude there's no clear evidence supporting its use.

Still, "groups that advocate for chelation and groups that oppose chelation will both find comfort in the results," said one expert not connected to the study, Dr. Stephen Green, associate chairman in the department of cardiology at North Shore University Hospital in Manhasset, N.Y.

Chelation therapy involves dozens of arduous infusions conducted over a period of years, aimed at leaching excess metals from the body. Patients typically also receive high doses of vitamins and minerals. The therapy has been offered to heart patients by some clinics across the United States for decades, although its use for this purpose has been considered controversial and it has never received approval as a heart disease treatment from the U.S. Food and Drug Administration.

The results of this latest study are published in the March 27 issue of the Journal of the American Medical Association. Findings from the same study were also presented earlier this month at the annual meeting of the American College of Cardiology (ACC) in San Francisco, and at last fall's annual meeting of the American Heart Association.

Speaking at the ACC meeting on March 10, the study's lead researcher said that the modest benefit noted in the study had not made him any more ready to recommend chelation therapy.

"These findings should stimulate further research, but are not by themselves sufficient to recommend the routine use of chelation therapy and high-dose vitamins in most patients," said Dr. Gervasio Lamas, chief of the Columbia University division of cardiology at Mount Sinai Medical Center, in Miami Beach, Fla.

The trial, which was funded by the U.S. National Institutes of Health, involved more than 1,700 patients from the United States and Canada who had suffered a previous heart attack. Most were already taking standard therapies such as daily aspirin, cholesterol-lowering statins or blood pressure medications.

In the new analysis of the data, the patients were divided into two groups: high-dose vitamin/mineral supplements plus chelation or "dummy" placebo infusions/supplements. Chelation therapy consisted of 40 three-hour sessions with the IV infusions spread over anywhere between 50 and 110 weeks. Doses of vitamins and minerals given were much higher than recommended daily intakes.

After an average follow-up of more than four and a half years, the team did see a slight benefit among the group who took the vitamins/minerals in combination with chelation therapy. Twenty-six percent of people in this group experienced some kind of cardiovascular event such as heart attack, stroke or hospitalization for angina (chest pain) -- less than the 30 percent seen among those who got placebo/placebo therapy only.

Still, the gap was not huge and Lamas, who does not use chelation therapy in his own practice, said he cannot recommend it at this time. The researchers also noted that the drop-out rate among participants was relatively high: 281 people in the placebo arm stopped treatment before the study's end, as did 233 of those taking chelation.

"The message really is a cautious message," Lamas said. "We brought something that has been an alternative medicine treatment into the realm of scientific inquiry and found unexpected results that may merit future research. However, we don't think that the results of any single trial are enough to carry this novel hypothesis into daily use for patients."

In an editorial published in JAMA, the journal's editor-in-chief, Dr. Howard Bauchner said that "based on full consideration of the strengths and limitations of [this study], the conclusion is clear and should influence practice -- these findings do not support the routine use of chelation therapy as secondary prevention for patients with previous [heart attack] and established coronary disease."

But Green said the debate over chelation's effectiveness may continue.

"The use of chelation therapy for coronary artery disease has had its advocates for decades, but predominantly outside of regular medical circles," Green noted. "This is because there has not been what was considered a good hypothesis to explain why it should work for coronary atherosclerosis [hardening of the arteries]."

Beyond that are safety concerns linked to the therapy's removal of calcium from the bloodstream. In the study, the researchers noted that the treatment "may cause hypocalcemia [abnormally low calcium in the blood] and death."

Speaking at the time of the ACC meeting presentation in San Francisco, cardiologist Dr. Tara Narula, associate director of the cardiac care unit at Lenox Hill Hospital in New York City, was similarly dubious of chelation's usefulness.

"Although it is noteworthy that chelation may be helpful, it is an expensive treatment and does carry significant side effects," she said.

More information

There's more on the care of heart attack patients at the U.S. National Heart, Lung, and Blood Institute.

SOURCES: Stephen Green, M.D., associate chairman, department of cardiology, North Shore University Hospital, Manhasset, N.Y.; Tara Narula, M.D., associate director, cardiac care unit, Lenox Hill Hospital, New York City; March 10, 2013, press briefing, American College of Cardiology annual meeting, San Francisco, with Gervasio Lamas, M.D., chief, Columbia University division of cardiology, Mount Sinai Medical Center, Miami Beach, Fla; March 27, 2013, Journal of the American Medical Association

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Modest alcohol consumption lowers risk and severity of liver disease
2. IUD Use Tied to Modest Weight Loss
3. Modest Health Care Spending Rise Expected for 2013: Report
4. Modest Weight Loss Can Reap Prolonged Health Benefits
5. Diabetes Drug May Offer Modest Weight Loss for Very Obese Teens: Study
6. SMART heart eases heart ache, targets cardiac patients emotional well-being
7. Erectile dysfunction drug may benefit cardiac function in young patients with heart defects
8. Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study
9. People With HIV at Higher Odds of Sudden Cardiac Death
10. Study: Heart damage after chemo linked to stress in cardiac cells
11. Study Spots Early Warning Signal for Sudden Cardiac Death
Post Your Comments:
Related Image:
Modest Cardiac Benefit From Chelation Therapy Not Enough to OK Use: Experts
(Date:11/28/2015)... PITTSBURGH, PA (PRWEB) , ... November 28, 2015 , ... ... Manalapan, N.J., has created the COUCH BUDDY. "I conceived of this design due to ... more comfort for couch users. It promotes relaxation and convenience, as well as increases ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... According ... carried out by the University of Toronto and the University of British Columbia suggested ... hospitalizations for head injuries. The article explains that part of the reason for the ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... progress through sharing, the 2016 Building Better Radiology Marketing Programs meeting ... begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... CBD ... Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography ... CAAHEP accredited colleges, as only one of twelve colleges and universities in the state ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... PHILADELPHIA , Nov. 27, 2015  Lannett ... that it has completed the acquisition of Kremers ... pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A. ... --> Lannett has acquired KU from UCB ... to certain adjustments, including a customary working capital ...
(Date:11/26/2015)... India , November 27, ... --> --> ... personal emergency response system (PERS) ... steadily for 5 years with ... region expected to see a ...
(Date:11/26/2015)... --> --> ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy can be efficiently combined with photodynamic therapy (PDT) ...
Breaking Medicine Technology: